Shares of Anthem BioSciences rose after Citi initiated coverage with a Buy rating and a target price of ₹870, implying over 20% upside. Analysts cited strong growth prospects, a robust portfolio of commercial molecules, sticky client relationships, and scalable manufacturing capabilities supporting long-term revenue visibility.
